Article Details
Retrieved on: 2025-09-28 06:22:43
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Goldman Sachs has initiated coverage on Immunome with a favorable Buy rating and set a price target at $26, highlighting its promising oncology ...
Article found on: stockstotrade.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here